Protara Therapeutics (TARA) Non Operating Income (2013 - 2026)
Protara Therapeutics (TARA) posted quarterly Non Operating Income of $1.8 million for Q1 2026, down 16.43% year-over-year from $2.2 million in Q1 2025, and up 4.23% quarter-over-quarter from $1.8 million in Q4 2025.
Protara Therapeutics (TARA) Non Operating Income (2013 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Non Operating Income for 14 consecutive years, with $1.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income fell 16.43% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $6.7 million (up 12.23% YoY), while the FY2025 annual figure was $7.1 million, up 55.99% from the prior year.
- Non Operating Income advanced to $1.8 million in Q1 2026 per TARA's latest filing, from $1.8 million in the prior quarter.
- Across five years, Non Operating Income topped out at $2.2 million in Q1 2025 and bottomed at $119000.0 in Q1 2022.
- Historically, Non Operating Income has averaged $1.0 million across 5 years, with a median of $846000.0 in 2023.
- Annual changes were most pronounced in 2022 — Non Operating Income soared 1560.0% — and 2026, when it fell 16.43%.
- Protara Therapeutics' Non Operating Income stood at $542000.0 in 2022, then surged by 51.29% to $820000.0 in 2023, then surged by 88.17% to $1.5 million in 2024, then advanced by 14.84% to $1.8 million in 2025, then climbed by 4.23% to $1.8 million in 2026.
- Business Quant data shows TARA's Non Operating Income at $1.8 million in Q1 2026, $1.8 million in Q4 2025, and $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Protara Therapeutics | 234.56 Mn | 234.56 Mn | - | 1.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.66 Mn |
| Mar 31, 2026 | 1.85 Mn |
| Dec 31, 2025 | 1.77 Mn |
| Sep 30, 2025 | 1.50 Mn |
| Jun 30, 2025 | 1.63 Mn |
| Mar 31, 2025 | 2.21 Mn |
| Dec 31, 2024 | 1.54 Mn |
| Sep 30, 2024 | 1.11 Mn |
| Jun 30, 2024 | 1.15 Mn |
| Mar 31, 2024 | 756,000.00 |
| Dec 31, 2023 | 820,000.00 |
| Sep 30, 2023 | 840,000.00 |
| Jun 30, 2023 | 846,000.00 |
| Mar 31, 2023 | 687,000.00 |
| Dec 31, 2022 | 542,000.00 |
| Sep 30, 2022 | 283,000.00 |
| Jun 30, 2022 | 166,000.00 |
| Mar 31, 2022 | 119,000.00 |
| Dec 31, 2021 | 59,000.00 |
| Sep 30, 2021 | 53,000.00 |